Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.66 |
| ▸ | CCKAR | P32238 | 8/20 | 0.46 |
| ▸ | CCKBR | P32239 | 8/20 | 0.46 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.45 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.44 |
| ▸ | GNPAT | O15228 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17401200 | 0.99 | GLP1R (0.67) | GLP1RCCKARCCKBRFOLH1GNPAT | |
| SCHEMBL19786830 | 0.99 | GLP1R (0.67) | GLP1RCCKARCCKBRFOLH1GNPAT | |
| SCHEMBL21099643 | 0.98 | GLP1R (0.66) | GLP1RCCKARCCKBR | |
| SCHEMBL16192883 | 0.98 | GLP1R (0.66) | GLP1RCCKARCCKBR | |
| SCHEMBL21099692 | 0.98 | GLP1R (0.66) | GLP1RCCKARCCKBR | |
| SCHEMBL16192882 | 0.98 | GLP1R (0.66) | GLP1RCCKARCCKBR | |
| SCHEMBL19307987 | 0.98 | GLP1R (0.66) | GLP1RCCKARCCKBR | |
| SCHEMBL19867142 | 0.97 | GLP1R (0.65) | GLP1RCCKARCCKBRFOLH1GNPAT | |
| SCHEMBL21099861 | 0.97 | GLP1R (0.65) | GLP1RCCKARCCKBRFOLH1GNPAT | |
| SCHEMBL16192886 | 0.97 | GLP1R (0.65) | GLP1RCCKARCCKBRFOLH1GNPAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10570184-B2 | GLP-1/glucagon receptor co-agonists for medical use | NOVO NORDISK A/S (DK) | 2020-02-25 | — | — | US | disclosed |
| US-20170101454-A1 | GLP-1/Glucagon Receptor Co-Agonists for Medical Use | NOVO NORDISK A/S (DK) | 2017-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170101454-A1 | GLP-1/Glucagon Receptor Co-Agonists for Medical Use | GLP1R, GCGR, GIPR | GLP1R 1/4885CCKAR 28/4885CCKBR 31/4885 |
| US-10570184-B2 | GLP-1/glucagon receptor co-agonists for medical use | GLP1R, GCGR, GIPR | GLP1R 1/4885CCKAR 26/4885CCKBR 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.